Literature DB >> 2106002

Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia.

M Adachi1, A Tefferi, P R Greipp, T J Kipps, Y Tsujimoto.   

Abstract

Most of human follicular lymphomas possess the t(14;18) chromosome translocation that juxtaposes the IgH gene to the 3' region of bcl-2 in a head-to-tail configuration. Here we show that the rearrangement of the bcl-2 gene occurs in a significant fraction (approximately of 10%) of B cell CLL. In all cases analyzed, breakpoints on chromosome 18 clustered at the 5' flanking region of the bcl-2 gene, and no rearrangements were found at the major or minor breakpoint clustering region (3' region of bcl-2 gene) typical of the t(14;18) chromosome translocation. All of the rearranged bcl-2 genes were juxtaposed with the Ig lambda or K genes in a head-to-head configuration. These results imply that the bcl-2 gene is preferentially linked to the IgL genes in CLL and could function in leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2106002      PMCID: PMC2187727          DOI: 10.1084/jem.171.2.559

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  Variant translocation of the bcl-2 gene to immunoglobulin lambda light chain gene in chronic lymphocytic leukemia.

Authors:  M Adachi; J Cossman; D Longo; C M Croce; Y Tsujimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

2.  Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas.

Authors:  L M Weiss; R A Warnke; J Sklar; M L Cleary
Journal:  N Engl J Med       Date:  1987-11-05       Impact factor: 91.245

3.  Juxtaposition of human bcl-2 and immunoglobulin lambda light chain gene in chronic lymphocytic leukemia is the result of a reciprocal chromosome translocation between chromosome 18 and 22.

Authors:  M Adachi; Y Tsujimoto
Journal:  Oncogene       Date:  1989-09       Impact factor: 9.867

4.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells.

Authors:  D L Vaux; S Cory; J M Adams
Journal:  Nature       Date:  1988-09-29       Impact factor: 49.962

5.  Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18.

Authors:  M L Cleary; J Sklar
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

6.  Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer.

Authors:  J J Yunis; G Frizzera; M M Oken; J McKenna; A Theologides; M Arnesen
Journal:  N Engl J Med       Date:  1987-01-08       Impact factor: 91.245

7.  Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma.

Authors:  Y Tsujimoto; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

8.  DNA rearrangements in human follicular lymphoma can involve the 5' or the 3' region of the bcl-2 gene.

Authors:  Y Tsujimoto; M M Bashir; I Givol; J Cossman; E Jaffe; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

9.  The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining.

Authors:  Y Tsujimoto; J Gorham; J Cossman; E Jaffe; C M Croce
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

10.  bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation.

Authors:  T J McDonnell; N Deane; F M Platt; G Nunez; U Jaeger; J P McKearn; S J Korsmeyer
Journal:  Cell       Date:  1989-04-07       Impact factor: 41.582

View more
  29 in total

1.  Proto-oncogene analysis in multiple myeloma.

Authors:  M Ladanyi; S Wang; R Niesvizky; H Feiner; J Michaeli
Journal:  Am J Pathol       Date:  1992-10       Impact factor: 4.307

Review 2.  Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications.

Authors:  George A Calin; Carlo M Croce
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

3.  Karyotypic and molecular abnormalities in chronic lymphocytic leukaemia.

Authors:  C D Fegan; F E Davies
Journal:  Clin Mol Pathol       Date:  1996-08

4.  Absence of t(14;18) major and minor breakpoints and of Bcl-2 protein overproduction in Reed-Sternberg cells of Hodgkin's disease.

Authors:  D C Louie; J A Kant; J J Brooks; J C Reed
Journal:  Am J Pathol       Date:  1991-12       Impact factor: 4.307

Review 5.  Genetic abnormalities in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia.

Authors:  M Merup
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

Review 6.  miR deregulation in CLL.

Authors:  Veronica Balatti; Yuri Pekarky; Lara Rizzotto; Carlo M Croce
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

7.  Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia.

Authors:  G Gaidano; E W Newcomb; J Z Gong; V Tassi; A Neri; A Cortelezzi; R Calori; L Baldini; R Dalla-Favera
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

8.  miR-15 and miR-16 induce apoptosis by targeting BCL2.

Authors:  Amelia Cimmino; George Adrian Calin; Muller Fabbri; Marilena V Iorio; Manuela Ferracin; Masayoshi Shimizu; Sylwia E Wojcik; Rami I Aqeilan; Simona Zupo; Mariella Dono; Laura Rassenti; Hansjuerg Alder; Stefano Volinia; Chang-Gong Liu; Thomas J Kipps; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-15       Impact factor: 11.205

9.  Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease.

Authors:  A Strasser; S Whittingham; D L Vaux; M L Bath; J M Adams; S Cory; A W Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

Review 10.  Causes and consequences of microRNA dysregulation in cancer.

Authors:  Carlo M Croce
Journal:  Nat Rev Genet       Date:  2009-10       Impact factor: 53.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.